Emmes, a United States-based full-service Clinical Research Organisation, announced on Monday1, that it has named Dr Paul VanVeldhuisen as the president of Emmes Public Sector.
Dr VanVeldhuisen has more than 25 years of experience in clinical research. He joined Emmes in 1993 and later became a principal investigator. He has held roles of increasing responsibility in the company. Dr VanVeldhuisen has a PhD in epidemiology from The George Washington University, an MS in biostatistics from the University of Washington and a BS in mathematics from Calvin University.
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits